Ensysce Biosciences (ENSC) Fundamental Analysis: Revenue, Earnings & Valuation

8.75 / 10

Outperform

Fundamental analysis reveals outstanding positioning (8.8/10). Favorable aspects: Interest coverage ratio (EBIT / Interest expense) (%) and PB-ROE, offset by weaknesses in Total operating revenue (YoY growth rate %) and Operating revenue (YoY growth rate %). Composite outlook: exceptionally strong.

Analysis Checks(6/10)

Revenue-MV

Value1.32

Score3/3

Weight84.81%

1M Return7.95%

Total operating revenue (YoY growth rate %)

Value-2.75

Score0/3

Weight-27.81%

1M Return-4.02%

Inventory turnover ratio

Value98.02

Score2/3

Weight-8.89%

1M Return-1.19%

Profit-MV

Value0.62

Score2/3

Weight37.01%

1M Return4.10%

PB-ROE

Value-0.88

Score2/3

Weight40.84%

1M Return4.39%

Fixed assets turnover ratio

Value81.64

Score1/3

Weight-12.87%

1M Return-1.72%

Interest coverage ratio (EBIT / Interest expense) (%)

Value39.04

Score2/3

Weight-8.25%

1M Return-1.07%

Operating revenue (YoY growth rate %)

Value-2.75

Score0/3

Weight-30.38%

1M Return-4.46%

Cost of sales ratio (%)

Value71.86

Score2/3

Weight-10.34%

1M Return-1.40%

Asset-MV

Value-0.72

Score1/3

Weight35.87%

1M Return3.90%

Is ENSC undervalued or overvalued?

ENSC scores 8.75/10 on fundamentals and holds a Discounted valuation at present. Backed by its -324.86% ROE, -200.85% net margin, -0.53 P/E ratio, 1.85 P/B ratio, and 65.24% earnings growth, these metrics solidify its Outperform investment rating.